both with stage IV pathologies. The entire study population was evaluated for PDL-1 before starting treatment, by IHC. Results: We included 58 patients, 33 patients (57%) had lung cancer and 25 (43%) had other types of tumors. When analyzing the toxicities of both groups it was observed that, the patients with lung cancer showed: Asthenia 20 patients (44%), Skin Rash 8 patients (18%), Diarrhea 3 patients (7%), hypothyroidism 2 patients (5%), liver toxicity 6 patients (13%) and hematological toxicity 6 patients (13%). In the second group patients exhibited: Asthenia 17 patients (61%), Skin Rash 4 patients (14%), Diarrhea 2 patients (7%), hypothyroidism 2 patients (7%) and hematological toxicity 3 patients (11%).
Conclusion:In this work, we can observe that in both groups there were expected toxicities. The most frequent one was asthenia, but the group with lung cancer showed greater hepatic and hematological toxicity with a significant difference compared to other tumors.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.